SCHEMBL21373634

SCHEMBL21373634

Cc1c[c]cn1Cc1ccc2c(c1)OCO2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CMA1 P23946 1/20 0.50
▸ TSHR P16473 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ CASP1 P29466 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ LMNA P02545 1/20 0.48
▸ PKM P14618 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ CHRNB2 P17787 1/20 0.44
▸ CHRNA7 P36544 1/20 0.44
▸ CHRNA4 P43681 1/20 0.44
▸ TAAR1 Q96RJ0 3/20 0.43
▸ SLC6A2 P23975 1/20 0.43
▸ SLC6A4 P31645 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20379142 0.82 SMN1; SMN2 (0.49) CMA1TSHRKDM4EKMT2AMAPT
SCHEMBL21373590 0.80 CMA1 (0.47) CMA1TSHRKDM4EKMT2AMAPT
SCHEMBL21381493 0.79 SMN1; SMN2 (0.47) CMA1TSHRKDM4EKMT2AMAPT
SCHEMBL21382022 0.77 CMA1 (0.44) CMA1TSHRKDM4EKMT2AMAPT
SCHEMBL21381489 0.77 KDM4E (0.50) CMA1KDM4EKMT2AMAPTMEN1
SCHEMBL20379138 0.77 MAPT (0.49) CMA1TSHRKDM4EMAPTHSD17B10
SCHEMBL28330007 0.77 CMA1 (0.53) CMA1TSHRKDM4EKMT2AMAPT
SCHEMBL28330025 0.75 TSHR (0.64) CMA1TSHRKDM4EKMT2AMAPT
SCHEMBL20379522 0.74 TSHR (0.52) CMA1TSHRKDM4EKMT2AMAPT
SCHEMBL21373504 0.74 TSHR (0.56) CMA1TSHRKDM4EKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3543231-A1 COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES ETH Zurich (CH) 2019-09-25 — — EP claimed
EP-3568133-B1 CELL-PROTECTIVE COMPOUNDS AND THEIR USE ETH ZUERICH (CH) 2023-12-13 — — EP disclosed
CN-116462666-A Cytoprotective compounds and uses thereof 瑞士苏黎世联邦理工学院 2023-07-21 — — CN disclosed
US-11628159-B2 Cell-protective compounds and their use ETH ZURICH (CH) 2023-04-18 — — US disclosed
US-20210015793-A1 COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES ETH ZURICH (CH) 2021-01-21 — — US disclosed
US-20190343802-A1 CELL-PROTECTIVE COMPOUNDS AND THEIR USE ETH Zürich (CH) 2019-11-14 — — US disclosed
EP-3543231-A1 COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES ETH Zurich (CH) 2019-09-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190343802-A1 CELL-PROTECTIVE COMPOUNDS AND THEIR USE SRPK2, SRSF2, SRPK1 CMA1 3847/4885TSHR 4051/4885KDM4E 4581/4885
US-20210015793-A1 COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES PPT1, SPTLC1, LPCAT1 CMA1 1512/4885TSHR 4321/4885KDM4E 2462/4885
US-11628159-B2 Cell-protective compounds and their use SRPK2, SRSF2, SRPK1 CMA1 3847/4885TSHR 4051/4885KDM4E 4581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback